Suono Bio has filed a notice of an exempt offering of securities to raise $3,000,000.00 in New Debt Financing.
According to filings with the U.S. Securities and Exchange Commission, Suono Bio is raising $3,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Scott Kellogg played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Suono Bio
Suono Bio is a biotechnology company harnessing its proprietary drug delivery platform to transform the treatment of difficult-to-treat diseases by enabling localized delivery of small molecules, biologics, nucleic acids, and gene therapies without the need for encapsulation. This novel approach can cure and/or treat a variety of diseases with superior effectiveness, ultimately revolutionizing therapeutic delivery all together.
To learn more about Suono Bio, visit http://www.suonobio.com/
Contact:
Scott Kellogg, Chief Executive Officer
617-299-1496
https://www.linkedin.com/in/scott-kellogg-4471743/
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.